GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58;

GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerou...

Dec 11, 2014 · GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58.

RAHWAY, N.J., Jan. 28, 2025 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today reaffirmed its commitment to defending the safety and efficacy of its HPV vaccines. Merck is a defendant in product liability lawsuits in the United States involving GARDASIL® (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and […]

Mar 15, 2024 · Product approval information for Human Papillomavirus 9-valent Vaccine, Recombinant also known as Gardasil 9.

Jun 12, 2020 · GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Now Approved for the Prevention of HPV-Related Cervical, Vaginal, Vulvar, Anal, Oropharyngeal and Other Head and Neck Cancers.

Proper Name: Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant Tradename: Gardasil Manufacturer: Merck & Co., Inc. Indications: Prevention of vulvar and vaginal cancer

Vaccination with GARDASIL may not result in protection in all vaccine recipients. GARDASIL has not been demonstrated to prevent HPV-related CIN 2/3 or worse in women older than 26 years...

GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58;

The 9-valent HPV vaccine protects against HPV types 16 and 18, which cause about 66% of cervical cancers and most other HPV-attributable cancers in the United States, and five additional cancer-causing types, which account for about 15% of cervical cancers.